SCHEMBL6430150

SCHEMBL6430150

CN1CCN([C@H]2CC[C@H](n3nc(-c4ccc(Oc5ccccc5)nc4)c4c(N)ncnc43)CC2)CC1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 13/20 0.82
LCK P06239 10/20 0.82
SRC P12931 9/20 0.82
TEK Q02763 9/20 0.82
KDR P35968 4/20 0.82
NUDT14 O95848 1/20 0.70
NUDT5 Q9UKK9 1/20 0.70
LYN P07948 2/20 0.61
FLT3 P36888 2/20 0.60
CSK P41240 2/20 0.60
BLK P51451 2/20 0.60
ITK Q08881 2/20 0.60
FGR P09769 1/20 0.60
JAK3 P52333 1/20 0.60
PLK4 O00444 1/20 0.59
DCLK1 O15075 1/20 0.59
PDPK1 O15530 1/20 0.59
PRKD3 O94806 1/20 0.59
MAP4K4 O95819 1/20 0.59
PAK4 O96013 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5804551 1.00 BTK (0.82) BTKLCKSRCTEKKDR
SCHEMBL5804554 1.00 BTK (0.82) BTKLCKSRCTEKKDR
Maleic Acid SCHEMBL5801746 0.94 BTK (0.72) BTKLCKSRCTEKKDR
Maleic Acid SCHEMBL5801744 0.94 BTK (0.72) BTKLCKSRCTEKKDR
Fumaric Acid SCHEMBL5801750 0.94 BTK (0.72) BTKLCKSRCTEKKDR
Fumaric Acid SCHEMBL5801748 0.94 BTK (0.72) BTKLCKSRCTEKKDR
SCHEMBL25468776 0.93 BTK (0.81) BTKLCKSRCTEKKDR
SCHEMBL6433141 0.90 BTK (1.00) BTKLCKSRCTEKKDR
SCHEMBL6430568 0.90 BTK (1.00) BTKLCKSRCTEKKDR
SCHEMBL6430567 0.90 BTK (1.00) BTKLCKSRCTEKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 BTK 1020/4885LCK 1011/4885SRC 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.